- Meglumine
-
- $6.00 / 1kg
-
2024-08-23
- CAS:6284-40-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 2000KG/Month
- meglumine
-
- $1.00 / 1g
-
2024-08-23
- CAS:6284-40-8
- Min. Order: 1g
- Purity: 98%
- Supply Ability: 1000
- Meglumine
-
- $0.00 / 25Kg/Drum
-
2024-08-22
- CAS:6284-40-8
- Min. Order: 1KG
- Purity: 99%min
- Supply Ability: 500kgs
|
| Meglumine Basic information |
| Meglumine Chemical Properties |
Melting point | 129-131.5 °C (lit.) | Boiling point | 331.88°C (rough estimate) | alpha | -16.5 º (c=10, H2O, on dry sub) | density | 1.2669 (rough estimate) | RTECS | LZ4295770 | refractive index | -16.5 ° (C=2, H2O) | storage temp. | 2-8°C | solubility | H2O: 0.1 g/mL, clear, colorless | form | Crystalline Powder | pka | pKa 9.39(H2O,t =30.0,I=0.05N2)(Approximate) | color | White to almost white | PH | 11 (10g/l, H2O, 20℃) | optical activity | [α]20/D 16.5±0.5°, c = 2% in H2O | Water Solubility | 100 g/100 mL (25 ºC) | Sensitive | Air Sensitive & Hygroscopic | Merck | 14,6078 | BRN | 385906 | InChIKey | MBBZMMPHUWSWHV-VZFHVOOUSA-N | LogP | -3.370 (est) | NIST Chemistry Reference | N-methylglucamine(6284-40-8) | EPA Substance Registry System | Meglumine (6284-40-8) |
Risk Statements | 36/37/38 | Safety Statements | 24/25 | WGK Germany | 3 | F | 3-10-23 | Autoignition Temperature | ~662 °F | TSCA | Yes | HS Code | 29221980 | Toxicity | LD50 orally in Rabbit: > 5000 mg/kg |
| Meglumine Usage And Synthesis |
Chemical Properties | white to almost white crystalline powder | Chemical Properties | Meglumine occurs as a white to slightly yellow-colored crystalline
powder; it is odorless or with a slight odor. | Uses | antiinflammatory | Uses | N-Methyl-D-glucamine is used in conjunction with iodinated organic compounds in contrast media viz. diatrizoate meglumine and iodipamide meglumine. It is useful in ion-exchange resins to chelate boron ions selectively. It is also used as an excipient in pharmaceuticals, in cosmetics and X-ray contrast media. It is also employed in the synthesis of surface active agents, pharmaceuticals and dyes. | Uses | excipient in cosmetics and X-ray contrast media | Production Methods | Meglumine is prepared by the imination of glucose and monomethylamine,
in an alcoholic solution, followed by catalytic
hydrogenation. | Definition | ChEBI: A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, whi
e its antimonate is used as an antiprotozoal in the treatment of leishmaniasis. | Brand name | Renovue
(Bracco). | General Description | Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Meglumine is a glucose-derived secondary amine which is widely used as an excipient in pharmaceutical formulations. | Pharmaceutical Applications | Meglumine is an organic base used as a pH-adjusting agent and
solubilizing agent, primarily in the preparation of soluble salts of
iodinated organic acids used as X-ray contrast media. | Safety | Meglumine is widely used in parenteral pharmaceutical formulations
and is generally regarded as a nontoxic material at the levels
usually employed as an excipient.
LD50 (mouse, IP): 1.68 g/kg | storage | Meglumine does not polymerize or dehydrate unless heated above
150°C for prolonged periods.
The bulk material should be stored in a well-closed container in a
cool, dry place. Meglumine should not be stored in aluminum
containers since it reacts to evolve hydrogen gas; it discolors if
stored in containers made from copper or copper alloys. Stainless
steel containers are recommended. | Purification Methods | Crystallise N-methyl-D(-)-glucamine from MeOH. Its solubility in H2O is 10%. [Karrer & Herkenrath Helv Chim Acta 20 83 1957 also for other N-alkyl derivatives, Beilstein 4 IV 1914.] | Incompatibilities | Incompatible with aluminum, copper, mineral acids, and oxidizing
materials. Differential scanning calorimetry studies suggest meglumine
is incompatible with glipizide. | Regulatory Status | Included in the FDA Inactive Ingredients Database (injections; oral
tablets). Included in parenteral medicines licensed in the UK. |
| Meglumine Preparation Products And Raw materials |
|